Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors
2026年5月6日 更新者:Xingchen Peng、West China Hospital
A Phase I, Open-Label, Dose-Escalation Clinical Study to Evaluate the Safety and Tolerability of Intratumoral Administration of Macrophage-Derived Exosomes With Cellular Mechanobiological Reprogramming in Patients With Advanced Solid Tumors
The goal of this phase I clinical trial is to evaluate the safety and tolerability of intratumoral injection of mechanically reprogrammed macrophage-derived exosomes (MRMEs) in adults aged 18-65 years with advanced solid tumors who have failed, are ineligible for, or are intolerant of standard therapies.
研究概览
地位
招聘中
研究类型
介入性
注册 (估计的)
9
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Xingchen Peng
- 电话号码:18980606753
- 邮箱:pxx2014@163.com
学习地点
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- 招聘中
- West China Hospital, Sichuan University
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- Age 18 to 65 years (inclusive) at screening, any gender.
- Histologically or cytologically confirmed advanced (unresectable or metastatic) solid tumors (including melanoma, soft tissue sarcoma, head and neck squamous cell carcinoma, etc.) that have failed standard therapy, have no standard treatment options, or are intolerant to standard treatment.
- Must have a primary lesion suitable for local injection, accessible by direct palpation or under ultrasound/CT image guidance.
- At least one measurable lesion per RECIST v1.1 criteria.
- ECOG performance status score of 0-2.
- Expected survival ≥ 3 months.
Adequate organ function within 7 days prior to treatment:
- Neutrophil count (NEUT#) ≥ 1.5×10^9/L; Platelets (PLT) ≥ 80×10^9/L; Hemoglobin ≥ 8 g/dL
- AST, ALT, ALP ≤ 2.5×ULN; Total bilirubin (TBIL) ≤ 1.5×ULN; Albumin ≥ 2.8 g/dL
- Serum creatinine ≤ 1.5×ULN or CCR > 60 ml/min
- INR ≤ 1.5; APTT ≤ 1.5×ULN
- Voluntarily participates, signs informed consent, and is able to comply with study visits and procedures.
Exclusion Criteria:
- Contraindications to intratumoral injection: inflammation or ulceration at injection site; severe bleeding tendency; abnormal or permanent body art (e.g., tattoos) at injection site interfering with local reaction observation.
- History of other malignancies (except cured basal cell carcinoma, squamous cell carcinoma of skin, superficial bladder cancer, cervical carcinoma in situ, intramucosal gastrointestinal cancer without recurrence for 5 years).
- Active autoimmune disease or history of autoimmune disease (including but not limited to immune-related neuropathy, multiple sclerosis, autoimmune neuropathy, Guillain-Barré syndrome, myasthenia gravis, SLE, connective tissue disease, scleroderma, IBD, autoimmune hepatitis, TEN, or Stevens-Johnson syndrome); except Type 1 diabetes on stable insulin dose.
- Anti-tumor vaccine within 4 weeks before first dose; live vaccines within 4 weeks before or during the study; major surgery or severe trauma within 4 weeks before first dose.
- Prior anti-tumor treatment toxicity not recovered to ≤ CTCAE v5.0 Grade 1.
- Serious medical conditions: NYHA Class II or higher heart dysfunction, ischemic heart disease, significant arrhythmia, poorly controlled diabetes (fasting glucose ≥ 10 mmol/L), uncontrolled hypertension (SBP > 150 mmHg and/or DBP > 100 mmHg), LVEF < 50%, QTc > 450 ms (male) or > 470 ms (female).
- Active tuberculosis or uncontrolled prior TB infection.
- Hyperthyroidism or organic thyroid disease (except hypothyroidism controlled with stable thyroid hormone replacement).
- Active infection or unexplained fever within 48 hours before first dose, or systemic antibiotics within 1 week before informed consent.
- Active HBV (HBV DNA ≥ 2000 IU/ml or 10^4 copies/ml), active HCV (HCV antibody positive and HCV RNA above detection limit), or known HIV positive or AIDS history.
- Known neurological or psychiatric disorders (e.g., epilepsy, dementia).
- Known history of drug abuse or alcohol abuse within 3 months.
- Pregnant or breastfeeding women; participants (or their partners) planning pregnancy or unwilling to use contraception from screening to 6 months after study completion.
- Receipt of any investigational drug within 4 weeks before first dose, or concurrent enrollment in another interventional clinical study.
- Any other factors judged by the investigator that may affect study completion.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dose Level 1: 1×10^10 Exosomes
Intratumoral injection of mechanobiologically reprogrammed macrophage-derived exosomes at a dose of 1×10^10 exosomes per injection, administered once every 2 weeks for 4 doses (3+3 dose escalation, Cohort 1).
|
Autologous macrophage-derived exosomes prepared from the participant's own peripheral blood monocytes.
Monocytes are isolated by apheresis, differentiated into macrophages, subjected to nuclear compression via a microfluidic device to induce mechanobiological reprogramming, and then exosomes are extracted and purified by ultracentrifugation.
Administered via intratumoral injection once every 2 weeks for 4 doses at a dose of 1×10^10 exosomes.
|
|
实验性的:Dose Level 2: 2.5×10^10 Exosomes
Intratumoral injection of mechanobiologically reprogrammed macrophage-derived exosomes at a dose of 2.5×10^10 exosomes per injection, administered once every 2 weeks for 4 doses (3+3 dose escalation, Cohort 2).
|
Autologous macrophage-derived exosomes prepared from the participant's own peripheral blood monocytes.
Monocytes are isolated by apheresis, differentiated into macrophages, subjected to nuclear compression via a microfluidic device to induce mechanobiological reprogramming, and then exosomes are extracted and purified by ultracentrifugation.
Administered via intratumoral injection once every 2 weeks for 4 doses at a dose of 2.5×10^10 exosomes.
|
|
实验性的:Dose Level 3: 5×10^10 Exosomes
Intratumoral injection of mechanobiologically reprogrammed macrophage-derived exosomes at a dose of 5×10^10 exosomes per injection, administered once every 2 weeks for 4 doses (3+3 dose escalation, Cohort 3).
|
Autologous macrophage-derived exosomes prepared from the participant's own peripheral blood monocytes.
Monocytes are isolated by apheresis, differentiated into macrophages, subjected to nuclear compression via a microfluidic device to induce mechanobiological reprogramming, and then exosomes are extracted and purified by ultracentrifugation.
Administered via intratumoral injection once every 2 weeks for 4 doses at a dose of 5×10^10 exosomes.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Dose-Limiting Toxicity (DLT)
大体时间:From first administration through Day 28 post-administration (approximately 4 weeks)
|
DLT is defined as treatment-related adverse events graded per NCI CTCAE v5.0 occurring during the DLT observation period, including grade ≥4 hematologic toxicity or grade ≥3 non-hematologic toxicity (with exceptions).
|
From first administration through Day 28 post-administration (approximately 4 weeks)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR)
大体时间:Up to 12 months
|
Proportion of participants achieving complete response (CR) or partial response (PR) per RECIST v1.1 criteria
|
Up to 12 months
|
|
Progression-Free Survival (PFS)
大体时间:Up to 24 months
|
Time from first administration to disease progression or death from any cause, assessed per RECIST v1.1
|
Up to 24 months
|
|
Overall Survival (OS)
大体时间:Up to 24 months
|
Time from first administration to death from any cause
|
Up to 24 months
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
大体时间:Up to 6 months
|
Number and severity of adverse events graded per NCI CTCAE v5.0
|
Up to 6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Raillard M, Love EJ, Murison PJ. Effect of predosing versus slow administration of propofol on the dose required for anaesthetic induction and on physiologic variables in healthy dogs. Vet Anaesth Analg. 2018 Jul;45(4):414-422. doi: 10.1016/j.vaa.2018.02.004. Epub 2018 Mar 6.
- Alatrash N, Narh ES, Yadav A, Kim MJ, Janaratne T, Gabriel J, MacDonnell FM. Synthesis, DNA Cleavage Activity, Cytotoxicity, Acetylcholinesterase Inhibition, and Acute Murine Toxicity of Redox-Active Ruthenium(II) Polypyridyl Complexes. ChemMedChem. 2017 Jul 6;12(13):1055-1069. doi: 10.1002/cmdc.201700240. Epub 2017 Jun 12.
- Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T, Seabra MC, Wilson MS. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity. 2014 Jul 17;41(1):89-103. doi: 10.1016/j.immuni.2014.05.019.
- Niu J, Liu Y. The Construction of English Smart Classroom Teaching Mode Based on Deep Learning. Comput Intell Neurosci. 2022 Aug 22;2022:9037010. doi: 10.1155/2022/9037010. eCollection 2022.
- Piccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023 Jan;4(1):9-26. doi: 10.1038/s43018-022-00473-z. Epub 2022 Dec 23.
- Wang H, Guo S, Kim SJ, Shao F, Ho JWK, Wong KU, Miao Z, Hao D, Zhao M, Xu J, Zeng J, Wong KH, Di L, Wong AH, Xu X, Deng CX. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics. 2021 Jan 1;11(5):2442-2459. doi: 10.7150/thno.46460. eCollection 2021.
- Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, Schmierer M, Kremp M, Ball M, Qureshi R, Schott BH, Sonawane P, DeLong SC, Christiano M, Swaby RF, Abramson S, Locke K, Barton D, Kennedy E, Gill S, Cushing D, Klichinsky M, Condamine T, Abdou Y. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025 Apr;31(4):1171-1182. doi: 10.1038/s41591-025-03495-z. Epub 2025 Feb 7.
- Song Y, Soto J, Chen B, Yang L, Li S. Cell engineering: Biophysical regulation of the nucleus. Biomaterials. 2020 Mar;234:119743. doi: 10.1016/j.biomaterials.2019.119743. Epub 2020 Jan 3.
- Kalukula Y, Stephens AD, Lammerding J, Gabriele S. Mechanics and functional consequences of nuclear deformations. Nat Rev Mol Cell Biol. 2022 Sep;23(9):583-602. doi: 10.1038/s41580-022-00480-z. Epub 2022 May 5.
- Song Y, Soto J, Chen B, Hoffman T, Zhao W, Zhu N, Peng Q, Liu L, Ly C, Wong PK, Wang Y, Rowat AC, Kurdistani SK, Li S. Transient nuclear deformation primes epigenetic state and promotes cell reprogramming. Nat Mater. 2022 Oct;21(10):1191-1199. doi: 10.1038/s41563-022-01312-3. Epub 2022 Aug 4.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2026年5月10日
初级完成 (估计的)
2027年3月1日
研究完成 (估计的)
2028年5月1日
研究注册日期
首次提交
2026年4月26日
首先提交符合 QC 标准的
2026年4月26日
首次发布 (实际的)
2026年5月4日
研究记录更新
最后更新发布 (实际的)
2026年5月11日
上次提交的符合 QC 标准的更新
2026年5月6日
最后验证
2026年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.